{"id":1913,"date":"2024-12-21T16:57:10","date_gmt":"2024-12-21T13:57:10","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=1913"},"modified":"2025-06-21T13:49:54","modified_gmt":"2025-06-21T10:49:54","slug":"uk-approves-givinostat-duvyzat-for-duchenne-muscular-dystrophy-treatment","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/de\/uk-approves-givinostat-duvyzat-for-duchenne-muscular-dystrophy-treatment\/","title":{"rendered":"Gro\u00dfbritannien erteilt Zulassung f\u00fcr Givinostat (Duvyzat) zur Behandlung der Muskeldystrophie Duchenne"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Givinostat conditionally approved to treat patients with Duchenne muscular dystrophy (DMD).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In a significant development for patients with Duchenne muscular dystrophy (DMD), the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation for the medicine givinostat, also known as Duvyzat.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This approval, announced on 20 December 2024, marks a crucial step forward in the treatment of this debilitating genetic disorder.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Givinostat is a nonsteroidal drug indicated for the treatment of patients aged 6 years of age and older with all genetic variants of DMD. [Read more: <a href=\"https:\/\/dmdwarrior.com\/duvyzat-givinostat-nonsteroidal-drug\/\" target=\"_blank\" data-type=\"post\" data-id=\"1462\" rel=\"noreferrer noopener\">What is Duvyzat (Givinostat)?<\/a>]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Givinostat conditionally approved to treat patients with Duchenne muscular dystrophy (DMD). In a significant development for patients with Duchenne muscular dystrophy (DMD), the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation for the medicine givinostat, also known as Duvyzat. This approval, announced on 20 December 2024, marks a crucial step [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1916,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45],"tags":[46,49,47,50,48],"class_list":["post-1913","post","type-post","status-publish","format-standard","has-post-thumbnail","category-approved-therapies-for-duchenne-muscular-dystrophy","tag-duvyzat","tag-england","tag-givinostat","tag-mhra","tag-uk"],"subtitle":"Die bedingte Zulassung der MHRA erlaubt die Anwendung von Givinostat bei Patienten mit DMD, die sechs Jahre oder \u00e4lter sind, und ist auf alle genetischen Varianten der Krankheit anwendbar. Diese Entscheidung folgt der Zulassung von Givinostat durch die US-amerikanische Food and Drug Administration (FDA) zu Beginn dieses Jahres.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/1913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/comments?post=1913"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/1913\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media\/1916"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media?parent=1913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/categories?post=1913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/tags?post=1913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}